Purchase Order 7571TE26P00088

<p>The Food and Drug Administration issued a purchase order to Schrodinger LLC on June 27, 2023, for a Small Molecule Drug Discovery Suite license with a ceiling value of $248,024.00. Work is performed in Portland, Oregon. The firm fixed-price order extends through July 30, 2028.</p>

This is a firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Schrodinger LLC, a division of Schrodinger, Inc. The contract is for a Schrodinger Suite software license with maintenance and support, with a ceiling value of $288,254. The contract has an ultimate completion date of June 27, 2028. Schrodinger LLC is a leading provider of advanced computational tools for drug discovery and materials science, primarily serving government agencies within the...

This is a firm-fixed-price purchase order worth $90,000.00 awarded by the Food and Drug Administration (FDA) to Schrodinger LLC, a division of Schrodinger, Inc. The contract is for the renewal of Schrodinger Suite software licenses, which provide advanced computational tools for drug discovery and materials science research. Schrodinger LLC is a leading provider of chemical simulation software and has received numerous federal contract awards, primarily from civilian agencies within the...

This is a firm-fixed-price purchase order awarded by a civilian federal agency, the Northeast Area of an unspecified agency, to Schrodinger LLC, a division of Schrodinger, Inc. The $8,199 contract is for the provision of Schrodinger's specialized chemical simulation software, including the Small Molecule Drug Discovery Suite, Schrodinger Suite, LiveDesign, Comptox, and Materials Science Suite. These software products are used to support drug review, research efforts, and computational...

The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a $239,240 firm-fixed-price contract to Schrodinger LLC, a division of Schrodinger, Inc., to provide the Schrodinger Software Suite. This contract is for Schrodinger's state-of-the-art computational modeling and simulation software used to support drug discovery and research efforts across various government agencies, including the National Institutes of Health (NIH), National Cancer Institute (NCI), and...

This is a firm fixed-price purchase order awarded by the National Cancer Institute, an agency within the U.S. Department of Health and Human Services, to Schrodinger LLC for the provision of Schrodinger molecular modeling software. The contract has a ceiling value of $232,500.00 and a period of performance ending on March 28, 2027. Schrodinger LLC is a leading provider of advanced chemical simulation software for pharmaceutical, biotechnology, and materials research applications. The company has...

<p>The National Library of Medicine awarded a purchase order to Schrodinger LLC for $149,600 on June 29, 2017, to renew Schrodinger licenses. The order carries a firm fixed price and is not set-aside. Performance is to take place in Portland, Oregon, with an ultimate completion date of June 30, 2018. The point of contact is Peter Steinbach at the National Library of Medicine, Bethesda, Maryland.</p>

<p>The Food and Drug Administration awarded a purchase order to Chemical Computing Group ULC for Molecular Operating Environment software licensing, with a ceiling value of $163,600.00 and an award date of June 29, 2026. Place of performance is Silver Spring, Maryland. The ultimate completion date is June 28, 2031. This is a firm fixed-price purchase order with no set-aside applied.</p>

This federal contract award was made by an unspecified U.S. government agency to Schrodinger, Inc., a for-profit organization that develops chemical simulation software for the pharmaceutical, biotechnology, and materials research industries. The $128,335.00 firm-fixed-price purchase order provides Schrodinger with 11-month floating software licenses for its MACROMODEL, GLIDE, and related software modules. The contract does not have a set-aside designation. Schrodinger is an experienced...

<p>The Food and Drug Administration issued a purchase order to Skylight Inc. valued at $4,281,769.26 on July 6, 2025, for complaint submission experience minimum viable product development. Performance will occur in Silver Spring, Maryland, with an ultimate completion date of January 6, 2027. The order carries firm fixed price terms and no small business set-aside.</p>